Eyenovia (EYEN) Competitors $1.01 +0.06 (+6.32%) Closing price 04/14/2025 04:00 PM EasternExtended Trading$0.98 -0.04 (-3.47%) As of 08:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EYEN vs. NLSP, BTAI, CANF, TCRT, DRMA, ADIL, SNGX, ONCO, KLTO, and AEZSShould you be buying Eyenovia stock or one of its competitors? The main competitors of Eyenovia include NLS Pharmaceutics (NLSP), BioXcel Therapeutics (BTAI), Can-Fite BioPharma (CANF), Alaunos Therapeutics (TCRT), Dermata Therapeutics (DRMA), Adial Pharmaceuticals (ADIL), Soligenix (SNGX), Onconetix (ONCO), Klotho Neurosciences (KLTO), and Aeterna Zentaris (AEZS). These companies are all part of the "pharmaceutical products" industry. Eyenovia vs. NLS Pharmaceutics BioXcel Therapeutics Can-Fite BioPharma Alaunos Therapeutics Dermata Therapeutics Adial Pharmaceuticals Soligenix Onconetix Klotho Neurosciences Aeterna Zentaris NLS Pharmaceutics (NASDAQ:NLSP) and Eyenovia (NASDAQ:EYEN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, community ranking, institutional ownership, media sentiment, dividends, valuation and profitability. Is NLSP or EYEN more profitable? NLS Pharmaceutics has a net margin of 0.00% compared to Eyenovia's net margin of -114,639.41%. NLS Pharmaceutics' return on equity of 0.00% beat Eyenovia's return on equity.Company Net Margins Return on Equity Return on Assets NLS PharmaceuticsN/A N/A N/A Eyenovia -114,639.41%-1,108.24%-139.36% Which has more volatility and risk, NLSP or EYEN? NLS Pharmaceutics has a beta of -0.21, indicating that its share price is 121% less volatile than the S&P 500. Comparatively, Eyenovia has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Which has preferable earnings & valuation, NLSP or EYEN? NLS Pharmaceutics has higher earnings, but lower revenue than Eyenovia. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNLS PharmaceuticsN/AN/A-$12.17MN/AN/AEyenovia$31.83K44.20-$27.26M-$58.40-0.02 Does the MarketBeat Community favor NLSP or EYEN? Eyenovia received 166 more outperform votes than NLS Pharmaceutics when rated by MarketBeat users. Likewise, 64.21% of users gave Eyenovia an outperform vote while only 57.14% of users gave NLS Pharmaceutics an outperform vote. CompanyUnderperformOutperformNLS PharmaceuticsOutperform Votes857.14% Underperform Votes642.86% EyenoviaOutperform Votes17464.21% Underperform Votes9735.79% Do analysts rate NLSP or EYEN? Eyenovia has a consensus target price of $2.00, suggesting a potential upside of 98.02%. Given Eyenovia's stronger consensus rating and higher probable upside, analysts plainly believe Eyenovia is more favorable than NLS Pharmaceutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NLS Pharmaceutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Eyenovia 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do institutionals and insiders believe in NLSP or EYEN? 25.8% of Eyenovia shares are owned by institutional investors. 16.4% of NLS Pharmaceutics shares are owned by company insiders. Comparatively, 7.1% of Eyenovia shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media refer more to NLSP or EYEN? In the previous week, Eyenovia had 1 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 3 mentions for Eyenovia and 2 mentions for NLS Pharmaceutics. NLS Pharmaceutics' average media sentiment score of 1.44 beat Eyenovia's score of 0.47 indicating that NLS Pharmaceutics is being referred to more favorably in the media. Company Overall Sentiment NLS Pharmaceutics Positive Eyenovia Neutral SummaryEyenovia beats NLS Pharmaceutics on 8 of the 14 factors compared between the two stocks. Remove Ads Get Eyenovia News Delivered to You Automatically Sign up to receive the latest news and ratings for EYEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EYEN vs. The Competition Export to ExcelMetricEyenoviaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.41M$6.35B$5.35B$7.58BDividend YieldN/A3.23%5.11%4.33%P/E Ratio-0.026.7721.7617.79Price / Sales44.20229.14376.0394.59Price / CashN/A65.6738.1534.64Price / Book0.065.886.443.99Net Income-$27.26M$141.32M$3.20B$247.24M7 Day Performance9.78%8.32%6.16%6.12%1 Month Performance-38.79%-12.93%-8.82%-7.11%1 Year Performance-97.70%-12.47%9.66%-0.85% Eyenovia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EYENEyenovia2.1936 of 5 stars$1.01+6.3%$2.00+98.0%-97.6%$1.41M$31,832.00-0.0240NLSPNLS PharmaceuticsN/A$1.42-4.2%N/A+869.3%$5.11MN/A0.006Short Interest ↓Gap DownBTAIBioXcel Therapeutics4.081 of 5 stars$1.56-4.3%$42.60+2,630.8%-95.9%$5.00M$2.27M-0.0590Positive NewsCANFCan-Fite BioPharma2.2796 of 5 stars$1.41-4.1%$14.00+892.9%-38.1%$4.99M$667,000.00-0.798Analyst ForecastNews CoverageGap DownTCRTAlaunos Therapeutics1.1114 of 5 stars$3.00+1.7%N/A-84.4%$4.80M$10,000.000.0040High Trading VolumeDRMADermata Therapeutics1.7389 of 5 stars$0.88-7.9%$6.00+578.7%-86.9%$4.80MN/A-0.058Short Interest ↑Gap DownADILAdial Pharmaceuticals2.9984 of 5 stars$0.72+13.7%$8.00+1,011.1%-68.9%$4.73MN/A-0.2220SNGXSoligenix1.7436 of 5 stars$1.87+1.6%N/A-68.3%$4.69M$840,000.00-0.2520Short Interest ↓News CoverageONCOOnconetix0.9034 of 5 stars$0.07flatN/A-98.8%$4.65M$1.87M0.0012Short Interest ↓Gap DownKLTOKlotho NeurosciencesN/A$0.16+6.2%N/AN/A$4.62MN/A0.00N/AGap DownAEZSAeterna ZentarisN/A$2.56-5.7%N/A-63.9%$4.59M$2.37M-0.1720 Remove Ads Related Companies and Tools Related Companies NLSP Competitors BTAI Competitors CANF Competitors TCRT Competitors DRMA Competitors ADIL Competitors SNGX Competitors ONCO Competitors KLTO Competitors AEZS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EYEN) was last updated on 4/15/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredElon’s Silver Play? Trump Clears the PathNothing is confirmed—yet. But Musk has disrupted every industry he's touched, and Trump's policies make the ti...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eyenovia, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eyenovia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EYEN Stock Free EYEN Stock Alerts